A current perspective on applications of macrocyclic-peptide-based high-affinity ligands.

A current perspective on applications of macrocyclic-peptide-based high-affinity ligands.
复制标题

DOI:
10.1002/bip.22900
复制
发表时间:
2016-11
期刊:
影响因子:
2.9
通讯作者:
Hipolito, Christopher John
Hipolito, Christopher John
中科院分区:
生物学4区
文献类型:
--
作者:
Leenheer, Daniel;ten Dijke, Peter;Hipolito, Christopher John

文献摘要

参考文献

被引文献

相似文献

单抗与其靶标具有高亲和力和高选择性。然而,作为治疗学或诊断学的工具,它们的大尺寸(∼150 kDa)减少了对组织的渗透,并防止被动细胞摄取。为了克服这些和其他问题,选择或设计了最小化的蛋白质支架,注意不损害结合亲和力或特异性。另一种方法是从最小的非抗体支架开始,从从头开始的文库中选择功能配体。我们将讨论几类抗体衍生的配体,即抗体、抗体体内和纳米体,以及非抗体衍生的配体,即单体体、亲和体和大环肽的结构、制备、应用、优缺点。尤其是随机非标准多肽集成发现(RAPID)系统产生的大环肽,其体积较小(通常为∼2 kDa),但能够执行通常由较大的蛋白质配体处理的任务。
Monoclonal antibodies can bind with high affinity and high selectivity to their targets. As a tool in therapeutics or diagnostics, however, their large size (∼150 kDa) reduces penetration into tissue and prevents passive cellular uptake. To overcome these and other problems, minimized protein scaffolds have been chosen or engineered, with care taken to not compromise binding affinity or specificity. An alternate approach is to begin with a minimal non‐antibody scaffold and select functional ligands from a de novo library. We will discuss the structure, production, applications, strengths, and weaknesses of several classes of antibody‐derived ligands, that is, antibodies, intrabodies, and nanobodies, and nonantibody‐derived ligands, that is, monobodies, affibodies, and macrocyclic peptides. In particular, this review is focussed on macrocyclic peptides produced by the Random non‐standard Peptides Integrated Discovery (RaPID) system that are small in size (typically ∼2 kDa), but are able to perform tasks typically handled by larger proteinaceous ligands.
DOI: 10.1016/j.joca.2013.08.015
发表时间: 2013-11-01
影响因子: 7
作者:
Chiusaroli, R.;Visentini, M.;Visintin, M.
通讯作者: Visintin, M.
DOI: 10.1073/pnas.96.24.13703
发表时间: 1999-11-23
影响因子: 11.1
作者:
Bessette, PH;Åslund, F;Georgiou, G
通讯作者: Georgiou, G
DOI: 10.18632/oncotarget.6925
发表时间: 2016-03-29
期刊: Oncotarget
影响因子: --
作者:
Amici C;Visintin M;Verachi F;Paolini F;Percario Z;Di Bonito P;Mandarino A;Affabris E;Venuti A;Accardi L
通讯作者: Accardi L
DOI: 10.1038/nbt1087
发表时间: 2005-05-01
影响因子: 46.9
作者:
Fang, JM;Qian, JJ;Jooss, K
通讯作者: Jooss, K
DOI: 10.1515/bc-2011-250
发表时间: 2012-05-01
影响因子: 3.7
作者:
de Veer, Simon J.;Swedberg, Joakim E.;Harris, Jonathan M.
通讯作者: Harris, Jonathan M.